Opexa

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Opexa

Postby sh8un » Fri Sep 01, 2006 7:19 pm

Hi everyone,
Not really sure what this means but Opexa is the company that is researching Tovaxin. I am hoping that this means more money for them which I hope will go towards research and marketing of the drug? Anyone with some stock market background that could clarify?
NN


<shortened url>
sh8un
Family Elder
 
Posts: 303
Joined: Wed May 03, 2006 3:00 pm
Location: Calgary, AB, Canada

Postby ljm » Fri Sep 01, 2006 11:05 pm

The link isn't working (its a problem with businesswire) but I think you're referring to Opexa's news release that its now listed on NASDAQ?

Thats generally considered a good thing...it means their shares are now being traded on a major exchange...whereas before they were traded "over the counter" or OTC. It means, err, well, for one thing they can attract institutional investors, which typically can't invest in OTC stock.

To get on a major exchange like NYSE or NASDAQ you need to meet certain requirements regarding revenue, cash on hand, share price, etc.
They did a 1/10 reverse split, which increased their share price, and they raised about $20m in new financing...both of which would have helped them get the listing.

(sorry if thats not the release you were looking at...)
User avatar
ljm
Family Elder
 
Posts: 153
Joined: Wed Mar 30, 2005 3:00 pm

Postby sh8un » Fri Sep 01, 2006 11:45 pm

Hi ljm
Thanx for the explanation. I WAS talking about the NASDAQ listing. That's really exciting. If anyone wants to see the real report you can go to the Opexa website and you will be able to see a link on the top left hand side. That's where I got this. http://www.pharmafrontierscorp.com/ Sorry about the link not working.
NN
sh8un
Family Elder
 
Posts: 303
Joined: Wed May 03, 2006 3:00 pm
Location: Calgary, AB, Canada

Postby ljm » Sat Sep 02, 2006 2:26 pm

Err...someone jump in here but...it would be good to look at the cmpany's quarterly or annual filings before geting excited (for some reason they won't load for me).

Nasdaq -- generally a good thing but lots of crappy companies manage to get listed. New financing -- generally a good thing but it depends entirely on terms, it can be part of a death spiral. Reverse stock split -- always suspect to me regardless of ir spin.

I think that trying to guess the prospect of a new therapy from the corporate activity of its company is probably not very accurate...my guess is that announcements of study results and status of fda applications are the only events that mean very much.
User avatar
ljm
Family Elder
 
Posts: 153
Joined: Wed Mar 30, 2005 3:00 pm

Postby Lyon » Sat Sep 02, 2006 2:35 pm

oo
Last edited by Lyon on Sat May 07, 2011 8:40 am, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 3:00 pm

Postby sh8un » Sun Sep 03, 2006 1:54 am

Hi ljm
Thanx for taking the time with this. I did not read all of this but is this what you are looking for? I just copied and pasted it from the pharmafrontiers site.





Related Links

Current Releases

Stock Quote

Standard & Poor's

SEC Filings

Mailing List

Releases Archives







Print this Release
August 14, 2006 12:30 PM US Eastern Timezone
Opexa Reports Second Quarter Financial Results
THE WOODLANDS, Texas--(BUSINESS WIRE)--Aug. 14, 2006--Opexa Therapeutics, Inc. (OTCBB:OPXA), a company involved in the development and commercialization of cell therapies, today reported financial results for the three and six months ended June 30, 2006. Highlights of the second quarter of 2006 include:


-- Changed corporate name to Opexa Therapeutics, Inc., and OTC/BB trading symbol to "OPXA"

-- Raised gross proceeds of $23 million in a private placement

-- Effected a 1-for-10 reverse stock split in preparation for application to Nasdaq for a listing

-- Initiated Phase IIb clinical trial with Tovaxin(TM) for the treatment of multiple sclerosis (MS)

-- Named Lynne Hohlfeld as chief financial officer

-- Appointed Michael S. Richmond, Gregory H. Bailey, M.D., David Hung, M.D. and Scott B. Seaman to the board of directors

Commenting on the quarter, David B. McWilliams, chief executive officer of Opexa, stated, "This has been a very dynamic and rewarding time for Opexa. We implemented an important capital restructuring and name change during the quarter, and completed a $23 million financing that provides the financial underpinnings for our Phase IIb trial with Tovaxin and funds our other business activities. We also strengthened our corporate governance with the addition of four new directors, each of whom brings a valuable skill set and perspective to Opexa."

He added, "On the clinical front, we achieved a very significant milestone with the initiation of our randomized, placebo-controlled Phase IIb trial to evaluate the effectiveness of our T cell-based therapeutic vaccine, Tovaxin, for treating MS. We believe that Tovaxin attacks the underlying cause of MS and has advantages over existing treatments for the disease, including lower relapse rates, quick onset of action, minimal side effects, less frequent injections and reduced patient fatigue."

Second Quarter Financial Results

Opexa reported no revenues for the three months ended June 30, 2006 or in the comparable prior-year period. General and administrative expenses in the second quarter of 2006 were $3,169,832, compared with $2,677,941 in the second quarter of 2005. The increase primarily is due to the increase in stock-based compensation expense in the 2006 period. On January 1, 2006 Opexa adopted Statement of Financial Accounting Standards No. 123 (revised 2004), "Share-Based Payment" ("SFAS 123R"), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including stock options and restricted stock based on estimated fair values. The Company elected to adopt the modified prospective transition method as provided by SFAS 123R and, accordingly, prior-year results have not been restated.

Research and development expenses were $1,554,912 in the 2006 second quarter, compared with $611,212 in the 2005 second quarter. The increase primarily was related to the initiation of the Phase IIb clinical trial, and a higher allocation of facilities and overhead costs to research and development due to increased development activities.

Interest expense was $184 in the second quarter of 2006, compared with $4,450,955 in the prior year. Interest expense in the 2005 quarter was due to notes payable that were then outstanding, which subsequently were converted into equity in June 2005 resulting in acceleration of the amortization of the discount related to the notes.

The Company recognized a loss on derivative instruments of $3,532,348 in the quarter. This loss was a result of the net unrealized (non-cash) change in the fair value of derivative instrument liabilities related to certain warrants.

Opexa reported a net loss for the second quarter of 2006 of $8,475,868, or $1.40 per share, compared with a net loss for the second quarter of 2005 of $7,747,740, or $6.99 per share. The increase in net loss primarily was due to stock-based compensation expense and loss on derivative instruments, offset in part by the decrease in interest expense.

The Company had cash and cash equivalents of $19,931,542 as of June 30, 2006, compared with $2,560,666 million as of December 31, 2005. In April 2006 the Company raised approximately $23 million in gross proceeds through a private placement of units to institutional and other accredited investors.

During the quarter, Lynne Hohlfeld, CPA, was named chief financial officer of Opexa, and Michael S. Richmond, Gregory H. Bailey, M.D., David Hung, M.D., and Scott B. Seaman were appointed to the Company's board of directors.

Year-to-Date Financial Results

Opexa reported no revenues in the six months ended June 30, 2006 or in the comparable prior-year period. General and administrative expenses for the first half of 2006 were $4,245,714, compared with $3,465,745 for the first half of 2005.

Opexa reported a net loss for the first half of 2006 of $10,446,178, or $2.57 per share, compared with a net loss for the first half of 2005 of $11,495,046, or $10.78 per share. The decrease in net loss primarily is due to the decrease in interest expense, partially offset by stock-based compensation expense and the loss on derivative instruments.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat several major disease areas such as MS, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated a Phase IIb clinical trial to evaluate effectiveness in treating MS. The Company holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences of the People's Republic of China. Opexa also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Therapeutics undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

OPEXA THERAPEUTICS, INC.
(formerly PharmaFrontiers Corp.)
(a development stage company)
CONSOLIDATED BALANCE SHEETS
(unaudited)

June 30, December 31,
2006 2005
------------ ------------
Assets

Current assets:
Cash and cash equivalents $19,931,542 $2,560,666
Other current assets 514,596 182,524
------------ ------------
Total current assets 20,446,138 2,743,190
------------ ------------

Intangible assets, net of $2,709,019 and
$1,888,891 of accumulated amortization 25,547,752 26,130,441
Property & equipment, net of $327,897 and
$256,082 of accumulated depreciation 1,262,048 479,996
Other assets - 388,210
------------ ------------
Total assets $47,255,938 $29,741,837
============ ============

Liabilities and Stockholder's Equity

Current liabilities:
Accounts payable $682,841 $689,467
Stock payable 112,440 -
Accrued expenses 643,088 240,309
Note payable 1,500,000 1,500,000
Derivative liability 10,039,863 6,761,655
------------ ------------
Total current liabilities 12,978,232 9,191,431
------------ ------------

Commitments and contingencies - -

Stockholders' equity:
Convertible preferred stock, no par value,
10,000,000 shares authorized, none issued
and outstanding - -
Common stock, $0.50 par value, 100,000,000
shares authorized, 6,696,784 and
2,061,955 shares issued and outstanding 3,348,351 1,030,977

Additional paid in capital 61,639,556 39,783,452
Deficit accumulated during the development
stage (30,710,201) (20,264,023)
------------ ------------
Total stockholders' equity 34,277,706 20,550,406
------------ ------------
Total liabilities and stockholders'
equity $47,255,938 $29,741,837
============ ============


OPEXA THERAPEUTICS, INC.
(a development stage company)
CONSOLIDATED STATEMENTS OF EXPENSES
Three and Six Months ended June 30, 2006 and 2005 and the
Period from January 22, 2003 (Inception) to June 30, 2006
(unaudited)

Three Months Three Months
Ended Ended
June 30, June 30,
2006 2005
-------------- --------------
General and administrative $3,169,832 $2,677,941
Depreciation and amortization 460,442 26,816
Research and development 1,554,912 611,212
Loss on disposal of assets - -
-------------- --------------
Operating loss (5,185,186) (3,315,969)

Interest income 198,785 11,979
Other income 43,065 7,501
Gain (loss) on derivative liability (3,532,348) -
Interest expense (184) (4,450,955)
Other expense - (296)
-------------- --------------
Net loss $(8,475,868) $(7,747,740)
============== ==============

Basic and diluted loss per share $(1.40) $(6.99)

Weighted average shares outstanding 6,039,561 1,108,215


Six Months Six Months Inception
Ended Ended through
June 30, June 30, June 30,
2006 2005 2006
--------------------------------------------
General and
administrative $4,245,714 $3,465,745 $5,449,227
Depreciation and
amortization 892,775 864,044 2,892,803
Research and development 2,293,362 1,255,476 14,651,249
Loss on disposal of
assets 362 - 480,294
--------------------------------------------
Operating loss (7,432,213) (5,585,265) (23,473,573)

Interest income 218,406 18,909 306,328
Other income 46,450 9,945 77,003
Gain (loss) on derivative
liability (3,278,208) - 618,633
Interest expense (613) (5,938,339) (8,238,592)
Other expense - (296) -
--------------------------------------------
Net loss $(10,446,178) $(11,495,046) $(30,710,201)
============================================

Basic and diluted loss
per share $(2.57) $(10.78) N/A

Weighted average shares
outstanding 4,063,473 1,066,461 N/A




Print this Release Releases Archives



©2005 PharmaFrontiers Corp. All Rights Reserved
Design + Programming: BlausenLisi
sh8un
Family Elder
 
Posts: 303
Joined: Wed May 03, 2006 3:00 pm
Location: Calgary, AB, Canada


Return to General Discussion

Who is online

Users browsing this forum: Youarethecure


Contact us | Terms of Service

cron